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Abstract
The composition of the human intestinal microbiota is linked to health status. The aim was to analyze the microbiota of
normal and colon cancer patients in order to establish cancer-related dysbiosis.
Patients and Methods: Stool bacterial DNA was extracted prior to colonoscopy from 179 patients: 60 with colorectal cancer,
and 119 with normal colonoscopy. Bacterial genes obtained by pyrosequencing of 12 stool samples (6 Normal and 6 Cancer)
were subjected to a validated Principal Component Analysis (PCA) test. The dominant and subdominant bacterial
population (C. leptum, C. coccoides, Bacteroides/Prevotella, Lactobacillus/Leuconostoc/Pediococcus groups, Bifidobacterium
genus, and E. coli, and Faecalibacterium prausnitzii species) were quantified in all individuals using qPCR and specific IL17
producer cells in the intestinal mucosa were characterized using immunohistochemistry.
Findings: Pyrosequencing (Minimal sequence 200 nucleotide reads) revealed 80% of all sequences could be assigned to a
total of 819 taxa based on default parameter of Classifier software. The phylogenetic core in Cancer individuals was different
from that in Normal individuals according to the PCA analysis, with trends towards differences in the dominant and
subdominant families of bacteria. Consequently, All-bacteria [log10 (bacteria/g of stool)] in Normal, and Cancer individuals
were similar [11.8860.35, and 11.8060.56, respectively, (P=0.16)], according to qPCR values whereas among all dominant
and subdominant species only those of Bacteroides/Prevotella were higher (All bacteria-specific bacterium; P=0.009) in
Cancer (-1.0460.55) than in Normal (-1.4060.83) individuals. IL17 immunoreactive cells were significantly expressed more in
the normal mucosa of cancer patients than in those with normal colonoscopy.
Conclusion: This is the first large series to demonstrate a composition change in the microbiota of colon cancer patients with
possible impact on mucosal immune response. These data open new filed for mass screening and pathophysiology investigations.
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Introduction
The human colon contains up to 10
14 bacteria [1]. They play a
major role in the fermentation of residual food, the modulation of
gut immune function, and protection against pathogens and
diseases [2–5]. Although the intestinal microbiota is largely
beneficial, changes in bacterial populations or in the products of
bacterial metabolism may contribute to disease.
In 1971, a study intended to identify associations between
human microbiota composition and colorectal carcinogenesis, but
it had to be abandoned because of technical difficulties. Later,
Moore and co-workers reported that 13 bacterial species were
significantly associated with a high risk of colon cancer and the
Western diet [1]. However, their results were somewhat uncon-
vincing because they investigated a small number of subjects and
no intestinal investigation i.e. radiology or colonoscopy was
performed. Nonetheless, since this study was carried out, the
human colonic microbiota has emerged as a major environmental
factor that appears to modulate the risk of colonic cancer, and
dysbiosis in the gut microbiota is now believed to be a factor
underlying the development of disease in genetically-predisposed
individuals. However, there is no evidence whether dysbiosis does
indeed occur in colon cancer.
Only a restricted set of bacterial populations in the nature have
been identified in the human body and about 80% of the human
bacteria identified by molecular tools i.e. metagenomic sequenc-
ing, are considered uncultivable [6]. Although some prevalent
bacterial species in normal individuals are now identified by using
whole genome sequencing [7], more than 60% of species remain
unknown and there is no data on how dysbiosis, if any, may occur
in colon cancer patients. Thus, DNA sequencing that targets
hypervariable regions within small ribosomal-subunit RNA genes,
especially 16S rRNA genes has made it possible to characterize the
biodiversity of the microbiota, which could lead to diseases (for a
review, see ref [8]). The 16S rRNA gene is a ribosomal component
that is conserved in all bacteria, and it contains variable sequences
that confer species specificity. According to this technique
predominant taxa in the human intestinal microbiota are reported
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groups and the Bifidobacterium genus [9]. The real-time quantitative
PCR (qPCR) approach has been adapted to evaluate these bacterial
populations in large numbers of samples [10–11], and changes in
microbiota components can now be studied in relation to health/
disease status. Species involved will impact experimental and
metabolic studies with new pathophysiology approaches. For
example, Bacteroides populations and more specifically those of
Bacteroides fragilis, have recently been shown to produce a
metalloprotease in colon cancer patients, but not in controls [12].
This bacteria species has been shown to induce mucosal regulatory
T-cell responses in the intestine involving TH17 cell recruitment in
animals [13–14] suggesting strongly they may alter homeostasis of
effector helper T-cell populations in the gut [14–15].
By using pyrosequencing technique, we report evidence that
colon cancer disease is linked with dysbiosis mainly due to a
change in dominant and subdominant species. By using qPCR, we
compared intestinal bacterial communities in normal individuals
and in those with colon cancer in the largest series so far reported
and show level of dysbiosis on dominant microbiota species. We
put these results in perspective with mucosal immune homeostasis
and stool marker for mass screening.
Results
Characteristics of individuals
They were classified as follows: Normal (n=119), who had
normal colonoscopy; those with colon (n=44) or rectal (n=16)
cancer (total n=60). Patients with cancer were gender-matched
(obviously two normal for one cancer) but were 10 years older than
those with normal colonoscopy (Table 1) like in our cohort (Table
S1 in Supplementary File S1) in because consecutive individuals
were included. Normal individuals less often reported a previous
personal history of polyps or a history of colon cancer in their
family and did not display difference concerning BMI. Thus, apart
from this item and age, they were matched for main other
characteristics including BMI and food or medicine uptake with
the cancer patient group (Table 1, Table S1 and Figure S1 in
Supplementary File S1).
Phylogeny issue based on taxon distribution
From all dataset, 1,210,781 trimmed sequences were obtained
and 978,710 of these could be assigned to a total of 819 taxa
(Table S2 in the Supplementary File S1). A rarefaction of data was
performed and gave adequate representation of the diversity of the
gut microbial community (Tables S1, Table S2 and Figure S3 in
the Supplementary File S1). We identified 18 bacterial genera with
an abundance of more than 1%, and these genera included 75% of
the sequences. Thirteen out of the 18 genera (Alistipes, Collinsella,
Bacteroides, Lachnospira, Prevotella, Subdoligranulum, Dorea, Faecalibacter-
ium, Roseburia, Coprococcus, Streptococcus, Bifidobacterium and Rumino-
coccus) corresponded to the human intestinal microbiota phyloge-
netic core [16]. PCAIV analysis also showed that about 5% of the
variability could be attributed to the disease status of each sample
(Normal versus Cancer; p,0.05), and the taxa indicative of the
microbiota of normal and cancer individuals were clearly
distinguished (Figure 1 and Figure S2 in supplementary File S1).
Furthermore, 55 out of the 66 bacterial species belonging to the
previously-described phylogenetic core were detected in these
samples. The Monte Carlo test showed that more than 7% of the
variability was impacted by health status (Normal versus Cancer;
p,0.05). The variation within person was low and negligible
compared to between person-variation (Figure 1 and Table S4 in
supplementary File S1).
Comparison of bacterial populations in the stools
All-bacteria levelsdidnotdifferintheNormaland Cancergroups
(Table 2), whereas a significant difference was observed for
Bacteroides/Prevotella group. This difference was related to the
elevated level of these bacteria in Cancer as compared to Normal
groups (Table 2). Taking all individuals together Bacteroides/Prevotella
group density level was not linked to the age or BMI (r=0.05;
p=0.46; see also Figure S1 in supplementary File S1). Taking all
individuals with cancer the bacterial levels were not linked with
tumor size or tumour staging referring to the international TNM
classification (Figure S1 in supplementary File S1) and small
invasive carcinomas could be associated with high levels of bacterial
density. The levels of Bacteroides/Prevotella group were not influenced
by other patient characteristics, such as age, BMI, the reason for the
colonoscopy, the previous history of polyps or of cancer in their
family (Table S1 in supplementary File S1), with size or location
(left-versusrightsided,orrectalversuscolon)ofthecancer(Table2).
For the other dominant or subdominant bacteria i.e. C. leptum
group, C. coccoides group, the Lactobacillus/Leuconostoc/Pediococcus
groups,theBifidobacteriumgenus,E.coli,andFaecalibacteriumprausnitzii
species, we did not find any difference between patients versus
Normal colonoscopy individuals.
IL17 immune cells and Bacteroides in the mucosa
These cells were found infiltrating majority of tumour samples
(score ++ to +++) and in the lamina propria of homologous normal
mucosa (score + to ++) in cancer patients’ tissue samples while they
were rarely or not detected in the normal mucosa (0 to +/-) in
normal individuals (Figure 2). No parametric statistical test showed
significant higher IL17 immunostained cell score in normal
mucosa of colon Cancer patients than in Normal colonoscopy
individuals (median +/- versus ++;p ,0.5). After double (CD3 and
Table 1. Characteristics of the individuals included in the
current study N=179.
Normal Cancer
1 p (lin)
Colonoscopy + Pathology N=119 N=60
Age: (mean 6 SD) 55.8611.6 67.1611.6 0.001
Gender, M: n (%)
BMI: (mean6 SD)
55 (46.2)
25.1 (0.47)
31 (51.6)
24.5 (0.85)
0.14
0.68
Past history of polyps: n (%) 27 (22.7) 4 (6.6) 0.001
Colon cancer in relatives
Yes, n (%) 67 (0.5) 16 (9.0) 0.003
Diabetes, yes n (%) 12 (10.1) 9 (15) 0.13
Hypercholesterolemia, n (%) 31 (26.4) 21 (35) 0.09
Particular nutriment
2
Regimen Yes, n (%) 21 (17.6) 11 (18.3) 0.26
Treatment, any
3, n (%) 93 (78.1) 45 (75) 0.26
Reason for colonoscopy: n (%)
Screening 44 (36.9) 10 (16.6)
Control for polyps 22 (18.5) 4 (6.6) ,0.001
Symptoms 53 (44.6) 46 (76.6)
1- includes invasive cancers (n=53), advanced adenomas (n=2) and large
villous tumours of at least 3 cm in diameter (n=5);
2- includes those individuals who are under any particular regimen (diabetes,
vegetarian, hyper proteic, hyper vitaminic etc…);
3- No antibiotics.
doi:10.1371/journal.pone.0016393.t001
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immunoreactive cells were found to be of CD3 marker in both
(Normal mucosa or homologous to cancer normal mucosa) cases
although all CD3 cells were not immunostained with IL17
antibody. However, IL17/CD3 ratios in normal colon mucosa
appeared no significantly different between Normal and Cancer
colonoscopy individuals (Figure 2C, D). These semi quantitative
immune cell findings were linked with specific tissue adherent
Bacteroides density (Figure 3). Bacteroides gene amplification product
was found 1000-fold more expressed in the stool than in colon
tissue samples as revealed by qPCR (Figure 3B). Furthermore, the
Bacteroides amplification product was significantly higher in colon
cancer patients’ tissues (normal as well as tumoral) than in normal
individuals’ tissues as assessed by qPCR and revealed by gel
analysis (Figure 3 and Figure S4 in supplementary File S1). In
colorectal cancer patients, Bacteroides gene amplification product
was significantly higher in tumour tissue than in normal
homologous tissue (Figure S5 in supplementary File S1).
Discussion
We report differences in the colon microbiota in individuals
with colon cancer versus those with a normal colonoscopy. We
showed that the distribution of bacterial genera in the microbiota
varied, depending on their disease status, and qPCR revealed
significant elevation of the Bacteroides/Prevotella population in
cancer patients that appeared to be linked with elevated IL17
producing cells in the mucosa of individuals with cancer.
This study compares individuals presenting with a normal or
diseased colonoscopy. Although those with a normal colonoscopy
were not healthy volunteers, they can be considered to constitute a
meaningful control group. This is because they were randomly
selected from amongst consecutive individuals who had been
referred for colonoscopy that was found to be normal. In order to
reduce the bias we selected 2 normal individuals for 1 cancer case.
Their characteristics matched those of the patients in the cancer
group, except for their age and cases of polyps or cancer in
relatives. Age differences reflect the epidemiological data in the
literature. Bacterial dysbiosis found in our study was clearly
independent from age. None of microbial differences observed in
this study was linked with age. Another difference between cases
and controls concerns higher prevalence of neoplasms in colon
cancer patients’ relatives. This might reflect the role of
environmental factors rather than germinal genetic alterations
since none of patients had stigmata of Lynch or polyposis
adenomatous familial PAF syndrome diseases.
Figure 1. Bacterial genera abundance differentiates cancer patients and normal colonoscopy individuals. Principal component
analysis, based on the 16S rRNA gene sequence abundance of 7 discriminates genera which represented at least 1% of microbiota abundance, was
carried out with 6 healthy individuals (N) and 6 cancer* patients (Ca) with two replicates (noted as mid1 and mid2). Two first components (PC1 and
PC2) were plotted and represented 70.83% of whole inertia. Individuals (represented by their sample id) were clustered and centre of gravity
computed for each class. * They all have been selected from stage I-II of TNM classification (see also Tables S2 and S3 and Figures S2&S3 in the
supplementary File S1).
doi:10.1371/journal.pone.0016393.g001
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has substantially contributed to revealing a difference in the
bacterial phylogenetic core in normal individuals and those
suffering from various diseases [7]. However this approach did
not include cancer disease. In order to verify whether phylogenetic
core was different in healthy individuals and cancer patients, 16S
rRNA genes have been targeted by pyrosequencing as an
alternative to the all bacteria genome sequencing. Indeed, the
V3-V4 variable region of 16S rRNA can be used to provide a
bacterial classification of the human microbiota [17] on the basis
of pyrosequencing. By using this technology, we clearly identified
more than 40,000 informative sequences on V3-V4 16S rRNA
gene region from each stool sample, in the present study and this
led to the construction of the phylogenetic core of microbiota [16].
This phylogenetic core was found to be different in cancer patients
versus normal individuals. The differences concerned particularly
dominant and sub dominant bacterial populations. It is very
unlikely that the differences we found by pyrosequencing could be
epiphenomenal, since all the patients were included through a
standardized procedure (gender and age-matched, conditions of
stool sampling and DNA extraction) and sequence similarities
between duplicates (within person-variation) was very high.
Consequently, main groups, genus and species out of dominant
and sub dominant bacterial populations, have been quantified by
qPCR which is now routinely used to quantify the bacterial
composition of the microbiota of healthy or diseased people or
animals [9,18]. The density of ‘‘all-bacteria’’ in stool samples did
not reflect the colonoscopy findings, although one (i.e.; Bacteroides)
out of the seven species investigated here was found to be higher in
cancer group individuals. All these methods are validated, and
routinely used [6]. Although pyrosequencing technique, which
should be considered as a semi quantitative tool indicated many
other bacterial species change, only main dominant and
subdominant species were quantified in the present study by
qPCR. Furthermore, molecular analyses include species-related
differences in probe permeability, and amplification properties,
and because of the relatively small number of probes available for
analyzing the many uncharacterized gut species [19], we cannot
exclude the possibility that we may have missed other significant
differences in microbial density. So, this should not exclude
Table 2. Composition of microbiota regarding dominant and
sub dominant bacteria groups according to the colonoscopy
and pathology results.
Control Cancer p-value
N 119 60 -
All -bacteria* 11.8860.35 11.8060.56 0.21
Clostridium/Leptum
group
{
20.00260.024 +0.00460.016 0.27
Clostridium/Coccoides
group
{
21.2360.45 21.2960.41 0.36
Bacteroides/Prevotella
group
{
21.4060.83 21.0460.55 0.009
E. colispecies
{ 23.7461.28 23.6661.34 0.25
Bifidobacterium
genus
{
22.0361.22 21.9161.06 0.90
Lactobacillus/Leuconostoc/
Pediococcus
group
{
22.3260.95 22.2460.85 0.27
Faecalibacterium/prausnitzii
species
{ {
21.0561.02 20.8460.80 0.72
n: represents the numbers of studied samples.
*All-bacteria results obtained by qPCR were expressed as mean of the log10
value 6 SD.
{Results were expressed as mean of normalized values 6 SD,
calculated as the log number of targeted bacteria minus the log number of all-
bacteria.
{Faecalibacterium prausnitzii is the major component of the Clostridium leptum
group.
doi:10.1371/journal.pone.0016393.t002
Figure 2. Tissue samples are immunostained by using specific antihuman IL17 goat antibody (1:40 concentration at room
temperature for 1 h) and revealed by DAB system and counterstained with haematoxylin with high magnifications in the windows.
Samples from the same individuals and colonic sites were submitted to DNA extraction and PCR. Interleukin 17 (IL17)-immunoreactive cells in colonic
tissues were mainly located in the lamina propria in the normal tissues [A: colonic normal mucosa from a normal individual (high magnification x40 at
the bottom), B: colonic normal mucosa from a patient with colon cancer (high magnification x40 at the bottom)] and infiltrated the tumour tissue in a
the same individual than in B [C: IL17 imlmunoreactive cells infiltrating the tumour with high magnification x40 at the bottom & D: In this double
staining IL17 and CD3, the goat anti-human IL-17 antibody was added first before staining with Naphthol/Fast (red) followed by the rabbit anti-
human CD3 antibody that was revealed with DAB substrate (brown); this showed that CD3 was not the only cell producing IL-17.
doi:10.1371/journal.pone.0016393.g002
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bacteria taxa or species that now call for further investigation on
the basis of high-throughput sequencing results for cancerous and
control microbiota. The rRNA gene–based sequencing can detect
the predominant members of the community, but these approach-
es may not detect the rare members of a community with
divergent target sequences. To overcome the limitations of single
gene–based amplicon sequencing by pyrosequencing, whole-
genome shotgun sequencing has emerged as an attractive strategy
for assessing complex microbial diversity in mixed populations [7].
Nevertheless, this is the largest microbiological investigation to
have been reported so far, and the large number of subjects
enrolled with known colonoscopy and histopathology character-
istics make it very robust and could open the way to new
pathophysiologic fields and new screening markers.
The reason for an association between Bacteroides/Prevotella group
density elevation as assessed by qPCR and malignant colon tumors is
not clear. All primers used for qPCR in this study were designed to
quantify dominant and sub dominant species as suggested by
pyrosequencing approach. Whether such microbiological differences
found in the present study are cause or consequence of tumour
finding at colonoscopy concerns mechanistic approach which was not
designed to be analyzed here and requires prospective studies.
However, we could speculate that Bacteroides/Prevotellagroup density is
probably not the consequence of tumour occurrence because their
levels were not correlated with tumour size or disease staging and
Bacteroides genus species could be detected from washed mucosa
suggesting it belongs to mucosal adherent bacteria groups. Primers
we designed targeted Bacteroides and Prevotella genus populations.
Changes in Prevotella have been only reported in the oral and gastric
cavities [20] without any link with tumor growth. In contrast,
Bacteroides genus populations and more specifically those of Bacteroides
fragilis, have recently been shown to produce a metalloprotease in
colon cancer patients, but not in controls [12] suggesting this species
sub population might favor carcinogenesis. It is noteworthy that
among the many mechanisms that may mediate associations between
microbiota and human health [21–22], pro-inflammatory and
immune cell activation in colon mucosa are of great importance in
relation to malignancy. Some members of the gut microbiota may
steer host T-cell responses [13,15] others may maintain homeostasis
of effector helper T-cell populations in the gut [14]. B.fragilishas been
shown to induce mucosal regulatory T-cell responses in the intestine
involving TH17 cell recruitment in experimental models [13–14]. Of
interest mucosa-adherent Bacteroides species in our study appears
higher in colon cancer patients than in normal colonoscopy
individualsinaproportionlinkedwithmucosalIL17immunoreactive
cell density. This is consistent with our previous study in human that
reported TH17 cells overexpression in more than 80% of sporadic
colon cancer micro environment [23]. IL17 immunoreactive cells
infiltrate more the homologous normal colon mucosa of colon cancer
patients than normal tissues in normal colonoscopy individuals as
assessed by immunohistochemistry or mRNA qPCR quantification
from the mucosa (data not shown). These might suggest T-cell
activation can be associated with mucosal IL17 change due to
Bacteroides as reported in animal models [13–14,21–22]. Briefly, these
data argued in favor of a disturbed immune response in colon cancer
tissues with IL-17 overproduction exacerbating [24–25] the disease
likely due to Bacteroides.
Additional interesting aspect of the microbiota is its potential
value as a marker of colon cancer since majority of patients could
be identified from an elevation of the Bacteroides/Prevotella
population with possibility of a quantitative test a cut-off based
on a specificity rate. As compared to the colonoscopy so far the
elevations of Bacteroides in the stool and/or IL17 immunoreactive
cells in the normal mucosa appear to be promising sensitive
markers.
Methods
From September 2004 to September 2006, 648 individuals with
an average or higher than average risk of CRC (e.g. with history of
cancer in relatives or a personal past history of polyps, or any
abdominal or intestinal related symptoms or anemia that required
colonoscopy), were included in a sample bank collection study. To
be eligible for inclusion, the patients had to have no previous
history of colon or rectal surgery, of diseases such as cancer, or of
inflammatory or infectious injuries of the intestine, and not to need
an emergency colonoscopy. Two weeks prior to the colonoscopy,
patients were included after giving informed consent and were
asked to give a fresh stool sample within 2 weeks up to three days
prior to the colonoscopy. The study was approved by ethical
committee of Val de Marne Paris-EST area that authorized
enrolling patients in all associated centers. All patients received
information about the study, its aims, and samples they should
give. All information was given by a typed letter written in French
and formal consent has been obtained in a triplicate copy form;
one of these was conserved by the patient, we keep one copy at the
department of clinical research (CIC) and the last copy is
conserved by the promoter (National institute of scientific research
in medicine-INSERM). So, a formal consent is available for each
patient. In all cases stool samples were collected prior to bowel
cleansing for colonoscopy. Any particular diets (diabetics,
vegetarians) and medications (anti-diabetic drugs, hypocholester-
olemics, and laxatives) during this period were recorded. An
anesthetist visited the participants at least three days prior to the
scheduled colonoscopy. The study period continued until
colonoscopy and pathology data had been checked, and the final
status could be assigned as ‘‘normal colonoscopy’’, ‘‘Tumour at
colonoscopy’’ or ‘‘other abnormalities at colonoscopy’’. They were
held in a collection bio-bank for pathophysiology or test screening
Figure 3. The PCR products corresponding to Bacteroides (108
pb) appeared to be similar to those of human Albumin (77 pb)
in the tissue but highly elevated in stool samples. In the normal
individual’s tissue (A) gel migration system shows Bacteroides/Albumin
ratios close to 1 whereas they appeared higher in homologous normal
(N) or tumour (Ca) mucosa in the colon cancer patient’s tissues (B). Note
that Bacteroides gene amplification product in stool is dramatically
higher than that detected from mucosal DNA; amplification is referred
to the human Albumin gene.
doi:10.1371/journal.pone.0016393.g003
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between individuals with tumoral and normal colonoscopies,
samples from 180 patients (one cancer patient for 2 individual with
normal colonoscopy) who were checked not taking antibiotics with
either ‘‘normal’’ or ‘‘cancer’’ findings were subjected to bacteria
DNA analysis in the current series.
Fecal samples and bacterial DNA extraction
Whole fresh stools were collected in sterile boxes, and within
4 hours 10 gr were frozen at 220uC, for analysis. Bacterial DNA
wasextractedfrom aliquotsoffeces, and afterthefinalprecipitation,
DNA was resuspended in 150 mL of TE buffer, and stored at
220uC for further analysis, as previously described [26].
Pyrosequencing analysis from stools
Bacterial DNA samples from 6 individuals (3 males and 3
females being randomly selected) with a normal colonoscopy, and
6 age- and gender-matched patients with invasive CCR of stage I
or II of TNM classification, were used to construct 12 DNA
libraries. The following universal 16SrRNA primers were used for
the PCR reaction: V3F (TACGGRAGGCAGCAG) [27] and
V4R (GGACTACCAGGGTATCTAAT) [28] to target the V3-
V4 region, which gives the lowest error rates[29].
Barcode sequences (GsFLX key) TCAG and MIDGsFLX (12
nucleotides) were attached between the 454 GsFLX adaptator
sequence and the forward primer V3F. The GsFLX key and the
454 GsFLX adaptator were attached to the reverse primer. The
concentration and quality of the PCR products were assessed with
Picogreen in order to obtain equal amounts of each of the samples
(10
8 molecules/ml), and then 16S rRNA gene amplicons were
sequenced on a Roche GS FLX 454 sequencer (Genoscreen, Lille,
France) and processed with standard protocol from manufacturer
(http://genoscreen.fr/). To validate the presence of specific
bacterial taxa in the 2 groups of patients despite the variability
due to the technical process, each DNA sample was sequenced in
duplicate. Thus 12 stool bacterial DNA extracts were submitted to
pyrosequencing analysis, with two replicates of each. These 24 sets
of sequences were submitted to intra individual and inter
individual analyses and classical diversity indexes were computed.
Common sequences in two duplicates were considered for each
individual; then inter individual and inter group analyses were
performed according to ‘‘Normal’’ versus ‘‘Cancer’’ status.
Quantitative PCR analysis
We used a real-time qPCR technique to investigate the
difference in bacterial densities within the microbiota between
normal and cancer patients’ stool (N=179) and mucosal DNA
(N=44). The primers and probes used in this study have been
described elsewhere [26], and are presented in Table S1
supplementary File S1. Real-time qPCR was performed using an
ABI 7000 Sequence Detection System with software version 1.2.3
(Applied-Biosystems, Foster City, Ca, USA), and total numbers of
bacteria were inferred from averaged standard curves and
expressed as log10 value, as previously described [26]. Values of
qPCR were obtained per patient and for each component of gut
microbiota (total n=180 patients, 60 with cancer and 119 with
normal colonoscopy, one missing sample). To overcome the fact
that faecal samples might contain more or less water, the data for
each faecal sample was normalized as previously described [26].
The level found for each particular dominant and sub-dominant
bacterial population was subtracted from the all-bacteria content,
and the results are expressed as the log of the number of bacteria
per gram of stool. These assays were used to compare the
composition of the intestinal microbiota of the 179 individuals and
results are expressed as means 6 SD in the normal, and cancer
patient groups. In addition, representative colon (N=32) or rectal
(N=12) normal tissue samples from 22 individuals with normal
colon and 22 patients with colon (N=16) or rectal (N=6) cancer
were submitted to DNA extraction and qPCR quantification
according the same procedure to analyze mucosal adherent
bacteria component. Colonic or rectal tissues were obtained after
surgery; pieces were washed and representative samples were
conserved either in formalin for histochemistry or frozen until
DNA extraction for human albumin and Bacteroides PCR process.
Immunohistochemistry
Tissue samples were selected for each case (normal and cancer
individuals), and paraffin-embedded 4-mm sections were used and
immunostaining was performed according to methods described
elsewhere [23,30]. Briefly, the goat anti-human IL-17 antibody
(diluted 1:40) was added for 2 h, and then staining was undertaken
using (Vectastain AP kit from Vector Laboratories, Burlingame,
CA, USA), and revealed by Naphtol/Fast Red (Sigma-Aldrich).
For quantifying the immunostained cells, five well oriented slide
samples/individual from normal tissues in either control or colon
cancer patients were examined at a magnification of 4006(for a 3-
mm-long epithelium sample in each case). Labelled cells per
millimeter were determined using an ocular grid. Immunostained
cells were counted on 10 consecutive fields and semi-quantitatively
scored (as +/-, +, ++ or +++) and classified. For IL17/CD3 double
staining, the goat anti-human IL-17 antibody (diluted 1:40) was
added for 2 h, and then staining was undertaken using Vectastain
AP kit from Vector Laboratories (Burlingame, CA, USA), and
revealed by Naphtol/Fast Red (Sigma-Aldrich). Rabbit anti-
human CD3 antibody (diluted 1:50 in PBS, Dako, France) was
added for 1 h, and staining carried out using the ImmPRESS
system (Vector Laboratories, Burlingame, CA, USA), and
visualization done with DAB substrate. Accordingly, these IL17
and CD3 immunoreactive cells were recognized on red colour and
brown colour, respectively. Double stained cells were similarly
counted on 10 consecutive fields and semi-quantitatively scored.
Statistical analyses
a) Sequence analysis and phylogenic classification
Raw sequencing reads were quality trimmed according to
published recommendations [31]. The trimmed sequences were
assigned to taxa using the default settings of the Classifier software
[32] to obtain a rapid classification of the bacterial genus.
Rarefaction curves and diversity indices were computed for each
sample using Vegan package (Community Ecology Package; R
package version 1.17-3). The abundance of each taxon was
subjected to Principal Component Analysis, with the health status
as an instrumental Variable (PCAIV). The link between health
status and taxon abundance was reached by a Monte Carlo test
with 999 replicates using package ADE4 as described [33]. To
avoid the background noise generated by the genus present at
lower levels, another PCA was carried out with the best
discriminating taxa having more than 1% of observed reads. To
assess the impact of colon cancer on the phylogenetic core species
as described previously by Tap and colleagues [16]. Blast software
was used to assign reads to the representative sequences of
Operational Taxonomic Units shared by at least 50% of
individual. The impact of cancer on the phylogenetic core was
also determined by a Monte Carlo test with 999 replicates.
b) qPCR data analysis of individuals’ stool samples
Dysbiosis in Colon Cancer
PLoS ONE | www.plosone.org 6 January 2011 | Volume 6 | Issue 1 | e16393All comparisons were performed by means of non parametric tests
with a p value of 0.05 as significant. Differences in bacteria levels
were searched for between the groups: normal patients and
cancers using Mann-Whitney no parametric test.
Supporting Information
File S1 Thisfilecontainsdescriptionofthewholecohort(TableS1)
from which subgroup of patients for microbiota analysis has been
selected. The subgroup’s characteristics are similar to those of the
whole cohort. Additional information on pyrosequencing analyses
(Tables S2 and Table S3), primers selected for qPCR of dominant
and sub dominant bacteria families (Table S4) as well as correlation
with patients’ characteristics such as BMI, diet regimen (Figure S1)
are given. Additional illustration of bacterial species abundance
belonging to the phylogenetic core differentiates cancer patients and
healthy individuals (Figure S2) and rarefaction analysis of the
pyrosequencingrevealsvalidityoftheresults(FigureS3).Formucosa-
adherent bacteria analysis, characterization of probes for targeting
the Bacteroides genus in mucosa samples are indicated and sequences
of amplification products from mucosa are indicated (Figure S4);
Bacteroides 16S rRNA and human Albumin genes assessed by Gel
electrophoresis are shown on normal and tumoral mucosa (Figure 5).
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